Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18

Showing 18 citing articles:

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 13
Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review
Rajan Thapa, A Magar, Jesus Shrestha, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access | Times Cited: 5
Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity
Dianying Zhang, Jingjing Zhao, Yujing Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer
Yunzhao R. Ren, Qinchuan Wang, Chenyang Xu, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 513-513
Open Access | Times Cited: 2
Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2
Ryosuke Sato, Hiroki Komatsuda, Takahiro Inoue, et al.
Head & Neck (2024) Vol. 46, Iss. 9, pp. 2233-2243
Closed Access | Times Cited: 2
The prevalence and prognostic value of systemic inflammation in good performance status patients with advanced, inoperable non‐small cell lung cancer receiving palliative radiotherapy: Comparison of composite ratios and cumulative scores
Josh McGovern, Fraser O'Rourke, Sarah Will, et al.
Cancer Medicine (2024) Vol. 13, Iss. 16
Open Access | Times Cited: 2
A Potential Biomarker of Dynamic Change in Peripheral CD45RA−CD27+CD127+ Central Memory T Cells for Anti-PD-1 Therapy in Patients with Esophageal Squamous Cell Carcinoma
Mei Sakuma, Kosaku Mimura, Shotaro Nakajima, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3641-3641
Open Access | Times Cited: 6
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
Sinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency
Fabrizio Nelli, Enzo Maria Ruggeri, Marta Schirripa, et al.
Current Oncology (2024) Vol. 31, Iss. 12, pp. 7647-7662
Open Access | Times Cited: 1
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer
Feifei Wei, Tetsuro Sasada
Genes and Immunity (2023) Vol. 25, Iss. 1, pp. 89-91
Closed Access | Times Cited: 3
Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review
Tomasz Jankowski, Natalia Krzyżanowska, Kamila Wojas‐Krawczyk, et al.
Oncology in Clinical Practice (2024) Vol. 20, Iss. 4, pp. 278-285
Open Access
Prognostic value of immunotherapy in advanced non-small cell lung cancer based on baseline and dynamic changes in hemoglobin, albumin, and platelets
Hui Su, Chao Yu, Guiming Sun, et al.
Biomolecules and Biomedicine (2024)
Open Access
Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer
So-yun Kim, Dongil Park, Pureum Sun, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 8, pp. 1888-1906
Open Access
Prognostic biomarkers for immunotherapy in esophageal cancer
Tong Xu, Meiyuan Jin, Lulu Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Advancing prognostic precision in gastric cancer with an immunoinflammatory index
Hongmei Zhang, Guohua Wang, Shanwen Sun, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 44, pp. 4754-4758
Closed Access
Progress in the Detection of Serological Tumor Markers in Lung Cancer
庸霖 白
Advances in Clinical Medicine (2024) Vol. 14, Iss. 05, pp. 2163-2167
Closed Access
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Yuening Dai, Xi Tian, Xuanting Ye, et al.
Cancer Drug Resistance (2024)
Open Access
Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics
Amani A. Alrehaili, Amal F. Gharib, Abdulraheem Ali Almalki, et al.
Cureus (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top